A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients

被引:73
作者
Zhong, Runbo [1 ]
Han, Baohui [1 ]
Zhong, Hua [1 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm Dis, Shanghai 200030, Peoples R China
关键词
Chemoimmunotherapy; Dendritic cell; Cytokine-induced killer cell; Non-small cell lung cancer;
D O I
10.1007/s13277-013-1132-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Dendritic cells (DC) play a crucial role in the induction of an effective antitumor immune response. Cytokine-induced killer (CIK) cells, a subset of T lymphocytes, have the capacity to eliminate cancer cells. This study was to evaluate the correlation between the frequency of DC/CIK immunotherapies following regular chemotherapy, the time-to-progression (TTP), and overall survival (OS) of advanced non-small lung cancer patients. Sixty patients with IIIB-IV non-small-cell lung carcinoma (NSCLC) were enrolled from August 2007 to December 2009 and were randomized into two groups. All 60 patients received four courses of navelbine-platinum (NP) chemotherapy. In one group, 30 patients were treated with adoptive autologous DC/CIK cell transfusion twice every 30 days. In the other group, the patients received immunotherapies more than twice every 30 days. The adverse effects, TTP, and OS were evaluated between the two groups. Median survival time of all 60 patients was 13.80 months. The 1-, 2-, and 3-year overall survival rates were 60.0, 21.7, and 15.0 %, respectively. The 1-, 2-, and 3-year overall survival rates of patients receiving more than two immunotherapies were 63.3, 30.0, and 23.3 %, and the rates of those receiving two immunotherapies were 56.7, 13.3, and 6.7 %, respectively. The difference between the two groups was statistically significant (P = 0.037). Compared with patients in the fewer immunotherapies group, TTP in the group receiving more immunotherapies significantly prolonged, with the median improving from 6.2 months (95 % CI, 5.35-9.24) to 7.3 months (95 % CI, 5.45-6.95; P = 0.034). The adverse effects of chemoimmunotherapy were tolerable. Advanced NSCLC patients can benefit from the combination of DC/CIK immunotherapies following conventional chemotherapy. More than two immunotherapies improved TTP and OS of those patients in this study.
引用
收藏
页码:987 / 994
页数:8
相关论文
共 20 条
[1]
Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs [J].
Aloysius, Mark M. ;
Mc Kechnie, Alastair J. ;
Robins, Richard A. ;
Verma, Chandan ;
Eremin, Jennifer M. ;
Farzaneh, Farzin ;
Habib, Nagy A. ;
Bhalla, Joti ;
Hardwick, Nicola R. ;
Satthaporn, Sukchai ;
Sreenivasan, Thiagarajan ;
El-Sheemy, Mohammed ;
Eremin, Oleg .
JOURNAL OF TRANSLATIONAL MEDICINE, 2009, 7
[2]
The future of cancer vaccines for non-small-cell lung cancer: Ongoing trials [J].
Choudhury, Aniruddha ;
Palma, Marzia ;
Mellstedt, Hakan .
CLINICAL LUNG CANCER, 2008, 9 :S37-S44
[3]
Vaccination with dendritic cells pulsed with apoptotic tumors in combination with Anti-OX40 and Anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice [J].
Cuadros, C ;
Dominguez, AL ;
Lollini, PL ;
Croft, M ;
Mittler, RS ;
Borgström, P ;
Lustgarten, J .
INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (06) :934-943
[4]
Estimates of cancer incidence and mortality in Europe in 2008 [J].
Ferlay, J. ;
Parkin, D. M. ;
Steliarova-Foucher, E. .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (04) :765-781
[5]
The Optimal Chemotherapy for Stage III Non-Small Cell Lung Cancer Patients [J].
Gadgeel, Shirish M. .
CURRENT ONCOLOGY REPORTS, 2011, 13 (04) :272-279
[6]
Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity [J].
Kalady, MF ;
Onaitis, MW ;
Emani, S ;
Abdel-Wahab, Z ;
Tyler, DS ;
Pruitt, SK .
JOURNAL OF SURGICAL RESEARCH, 2004, 116 (01) :24-31
[7]
Targeting the Immune System in Non-Small-Cell Lung Cancer: Bridging the Gap Between Promising Concept and Therapeutic Reality [J].
Kelly, Ronan J. ;
Gulley, James L. ;
Giaccone, Giuseppe .
CLINICAL LUNG CANCER, 2010, 11 (04) :228-237
[8]
A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma [J].
Leemhuis, T ;
Wells, S ;
Scheffold, C ;
Edinger, M ;
Negrin, RS .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (03) :181-187
[9]
Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery [J].
Li, Hui ;
Wang, Changli ;
Yu, Jinpu ;
Cao, Shui ;
Wei, Feng ;
Zhang, Weihong ;
Han, Ying ;
Ren, Xiu-bao .
CYTOTHERAPY, 2009, 11 (08) :1076-1083
[10]
Cellular immunotherapy and autologous transplantation for hematologic malignancy [J].
Margolin, KA ;
Negrin, RS ;
Wong, KK ;
Chatterjee, S ;
Wright, C ;
Forman, SJ .
IMMUNOLOGICAL REVIEWS, 1997, 157 :231-240